-
581
-
582
-
583
Impairment of cocaine-mediated behaviours in mice by clinically relevant Ras-ERK inhibitors
Published 2016-08-01Get full text
Article -
584
-
585
-
586
-
587
-
588
Economic and Clinical Impact of Stroke and Warfarin Use for Patients with Non-valvular Atrial Fibrillation
Published 2013-11-01“…**Methods:** This was a retrospective analysis of medical and pharmacy claims of NVAF patients from a large commercial health insurance database (01/01/2005-12/31/2007). …”
Get full text
Article -
589
Glycogen Storage Disease Type Ia: A Retrospective Claims Analysis of Complications, Resource Utilization, and Cost of Care
Published 2025-01-01“…Healthcare use and costs were assessed by setting of care (inpatient, outpatient, physician office, emergency department, and pharmacy). **Results:** Overall, 557 patients with GSDIa and 5570 matched comparators (male, 63%; adults, 67%) were identified. …”
Get full text
Article -
590
Exploring drug utilization patterns, healthcare resource utilization, and epidemiology of rheumatoid arthritis in Colombia: a retrospective claims database study
Published 2025-02-01“…We estimated the age-standardized incidence and prevalence of RA each year, drug utilization patterns for disease-modifying antirheumatic drugs (DMARDs) and glucocorticoids, rates of medical consultations, emergency room visits, and hospitalizations, and associated comorbidities and healthcare-related and pharmacy-related costs. Results Overall, 327,430 unique patients with RA between 2017 and 2022 were included in the analysis, comprising 94,093 incident cases and 722,569 prevalent cases. …”
Get full text
Article -
591
-
592
Randomised feasibility study of an intestinal adsorbent in acute diarrhoea in The Gambia
Published 2025-01-01Get full text
Article -
593
Patterns of Comorbidity and Multimorbidity Among Patients With Multiple Sclerosis in a Large US Commercially Insured and Medicare Advantage Population
Published 2022-11-01“…Eligibility criteria were (1) at least 3 MS-related inpatient/outpatient (ICD-10-CM: G35), or disease-modifying therapy claims within 1 year (date of first claim = index date); (2) Aetna commercial health plan or Medicare Advantage medical and pharmacy benefits at least 12 months pre-/post-index; and (3) age 18 and older. …”
Get full text
Article -
594
-
595
-
596
-
597
-
598
-
599
-
600
Quzhou Aurantii Fructus Flavonoids Ameliorate Inflammatory Responses, Intestinal Barrier Dysfunction in DSS-Induced Colitis by Modulating PI3K/AKT Signaling Pathway and Gut Microbi...
Published 2025-02-01“…Haiou Wang,1 Wenkang Huang,1 Xiaoya Pan,1 Meizi Tian,1 Jiahui Chen,1 Xiaotong Liu,1 Qin Li,1 Jianhua Qi,2 Yiping Ye,1 Lijuan Gao1 1School of Pharmacy, Hangzhou Medical College, Hangzhou, 310013, People’s Republic of China; 2College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, People’s Republic of ChinaCorrespondence: Lijuan Gao; Yiping Ye, Hangzhou Medical College, 182 Tianmushan Road, Hangzhou, Zhejiang, 310013, People’s Republic of China, Email gaolijuan04141002@126.com; yeyiping2005@163.comPurpose: To explore the protective effect and underlying mechanism of Quzhou Aurantii Fructus flavonoids (QAFF) on Ulcerative colitis (UC).Methods: The constituents of QAFF were accurately determined by ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS). …”
Get full text
Article